Marcus Maurer spends much of his time researching Immunology, Dermatology, Omalizumab, Immunoglobulin E and Internal medicine. His biological study spans a wide range of topics, including Etiology, Pathology and Chronic disease. The Omalizumab study combines topics in areas such as Adverse effect, Randomized controlled trial and Solar urticaria.
Marcus Maurer works mostly in the field of Immunoglobulin E, limiting it down to concerns involving Autoantibody and, occasionally, Autoimmunity and Thyroid peroxidase. The Chronic urticaria research he does as part of his general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science. Cross-sectional study is closely connected to Quality of life in his research, which is encompassed under the umbrella topic of Allergy.
Marcus Maurer focuses on Immunology, Dermatology, Internal medicine, Omalizumab and Angioedema. Immunology is represented through his Mast cell, Immunoglobulin E, Inflammation, Allergy and Immune system research. His research in the fields of Hereditary angioedema, Cold urticaria, Physical urticaria and Atopic dermatitis overlaps with other disciplines such as In patient.
His Internal medicine study which covers Placebo that intersects with Anesthesia. His Omalizumab research focuses on Chronic urticaria and how it relates to Intensive care medicine. His Quality of life research includes elements of Physical therapy, Severity of illness and Disease.
Marcus Maurer mostly deals with Omalizumab, Dermatology, Immunology, Angioedema and In patient. His Omalizumab study combines topics in areas such as Internal medicine, Quality of life, Chronic urticaria and Antihistamine. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Placebo and Depression.
Marcus Maurer works in the field of Dermatology, focusing on Hereditary angioedema in particular. His work in the fields of Immunoglobulin E, Autoimmunity, Mast cell and Basophil overlaps with other areas such as Pandemic. Marcus Maurer interconnects Treatment options, Cold urticaria, MEDLINE and Intensive care medicine in the investigation of issues within Angioedema.
The scientist’s investigation covers issues in Internal medicine, Quality of life, Omalizumab, Angioedema and Immunology. His study looks at the relationship between Internal medicine and topics such as Placebo, which overlap with Attack rate, Standard therapy, Gastroenterology and Phases of clinical research. The various areas that Marcus Maurer examines in his Quality of life study include Visual analogue scale and Depression.
He combines subjects such as Anti-nuclear antibody, Dermatology Life Quality Index, Guideline and Antihistamine with his study of Omalizumab. His Angioedema research is multidisciplinary, incorporating elements of Pregnancy, Patient-reported outcome and Chronic urticaria. His work on Autoimmunity and Pathogenesis as part of his general Immunology study is frequently connected to Current, Pandemic and Stress, thereby bridging the divide between different branches of science.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.
T Zuberbier;W Aberer;R Asero;A H Abdul Latiff.
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria.
T. Zuberbier;R. Asero;C. Bindslev-Jensen;G. Walter Canonica.
EAACI/GA2LEN/EDF guideline: management of urticaria
T. Zuberbier;C. Bindslev‐Jensen;W. Canonica;C. E. H. Grattan.
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.
T Zuberbier;R Asero;C Bindslev-Jensen;G Walter Canonica.
Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper
Mk K. Church;Mk K. Church;M. Maurer;Fer E. R. Simons;C. Bindslev-Jensen.
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Marcus Maurer;Sabine Altrichter;Thomas Bieber;Tilo Biedermann.
The Journal of Allergy and Clinical Immunology (2011)
Mast cells are required for normal healing of skin wounds in mice.
Karsten Weller;Kerstin Foitzik;Ralf Paus;Wolfgang Syska.
The FASEB Journal (2006)
Mast cells--key effector cells in immune responses.
Martin Metz;Marcus Maurer.
Trends in Immunology (2007)
Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity
P. Staubach;A. Eckhardt-Henn;M. Dechene;A. Vonend.
British Journal of Dermatology (2006)
Epidemiology of urticaria: a representative cross-sectional population survey.
T. Zuberbier;M. Balke;M. Worm;G. Edenharter.
Clinical and Experimental Dermatology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: